DE69330745T2 - Chemerische immunogene - Google Patents

Chemerische immunogene

Info

Publication number
DE69330745T2
DE69330745T2 DE69330745T DE69330745T DE69330745T2 DE 69330745 T2 DE69330745 T2 DE 69330745T2 DE 69330745 T DE69330745 T DE 69330745T DE 69330745 T DE69330745 T DE 69330745T DE 69330745 T2 DE69330745 T2 DE 69330745T2
Authority
DE
Germany
Prior art keywords
protein
piv
rsv
gene sequence
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330745T
Other languages
English (en)
Other versions
DE69330745D1 (de
Inventor
H Klein
Run-Pan Du
E Ewasyshyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd filed Critical Aventis Pasteur Ltd
Publication of DE69330745D1 publication Critical patent/DE69330745D1/de
Application granted granted Critical
Publication of DE69330745T2 publication Critical patent/DE69330745T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69330745T 1992-01-06 1993-01-05 Chemerische immunogene Expired - Lifetime DE69330745T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200117A GB9200117D0 (en) 1992-01-06 1992-01-06 Production of recombinant chimeric proteins for vaccine use
PCT/CA1993/000001 WO1993014207A1 (en) 1992-01-06 1993-01-05 Chimeric immunogens

Publications (2)

Publication Number Publication Date
DE69330745D1 DE69330745D1 (de) 2001-10-18
DE69330745T2 true DE69330745T2 (de) 2002-05-29

Family

ID=10708117

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330745T Expired - Lifetime DE69330745T2 (de) 1992-01-06 1993-01-05 Chemerische immunogene

Country Status (16)

Country Link
US (13) US6225091B1 (de)
EP (1) EP0621898B1 (de)
JP (1) JP3290662B2 (de)
KR (1) KR100208310B1 (de)
AT (1) ATE205535T1 (de)
AU (1) AU667502B2 (de)
CA (1) CA2126863C (de)
DE (1) DE69330745T2 (de)
DK (1) DK0621898T3 (de)
ES (1) ES2164070T3 (de)
FI (1) FI117514B (de)
GB (1) GB9200117D0 (de)
NO (1) NO316622B1 (de)
PT (1) PT621898E (de)
RU (1) RU2123047C1 (de)
WO (1) WO1993014207A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AU5980899A (en) * 1998-09-25 2000-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
CN100354425C (zh) 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
KR100940776B1 (ko) * 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 사람-소 키메라 파라인플루엔자바이러스(ｐｉｖ) 백신
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
CN101921732A (zh) 2001-01-19 2010-12-22 维洛诺瓦蒂夫公司 在易感哺乳动物中引起呼吸道疾病的病毒
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
IL163646A0 (en) 2002-02-21 2005-12-18 Vironovative Bv Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
US7402427B2 (en) * 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
JP2005533861A (ja) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド 抗ＲＳＶ、抗ｈＭＰＶ、および抗ＰＩＶ抗体を使用するＲＳＶ、ｈＭＰＶ、およびＰＩＶの治療法と予防法
WO2004066961A2 (en) * 2003-01-20 2004-08-12 St. Jude Children's Research Hospital Use of sendai virus as a human parainfluenza vaccine
CA2520671C (en) * 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
EP2391383B1 (de) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimiertes hepatitis b virus core antigen (hbcag)
EA201270062A1 (ru) * 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
WO2012103496A2 (en) * 2011-01-28 2012-08-02 Medimmune, Llc Expression of soluble viral fusion glycoproteins in mammalian cells
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
US9662379B2 (en) 2011-12-02 2017-05-30 Rhode Island Hospital Vaccine for falciparum malaria
KR102435054B1 (ko) 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
US20160324954A1 (en) 2013-05-15 2016-11-10 Chrontech Pharma Ab Immunogenic compositions for inhibiting hepatitis d virus
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
US4722898A (en) * 1985-04-29 1988-02-02 Minnesota Mining And Manufacturing Company Immobilization of biological cells in polytetrafluoroethylene matrix
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
EP0316695B1 (de) * 1987-11-16 1993-03-31 F. Hoffmann-La Roche Ag Rekombinante HIV-2 Polypeptide
AU617739B2 (en) * 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
ATE105334T1 (de) * 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
FR2636842B1 (fr) 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0421626A1 (de) 1989-09-19 1991-04-10 Merck & Co. Inc. Vakzin gegen AIDS und Hepatitis B
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
JP3290662B2 (ja) 2002-06-10
CA2126863C (en) 1999-08-10
US7498153B2 (en) 2009-03-03
US7619063B2 (en) 2009-11-17
US7671186B2 (en) 2010-03-02
FI943211A0 (fi) 1994-07-05
EP0621898A1 (de) 1994-11-02
US7514535B2 (en) 2009-04-07
US6168786B1 (en) 2001-01-02
US20080032342A1 (en) 2008-02-07
US20080312412A1 (en) 2008-12-18
US6033668A (en) 2000-03-07
CA2126863A1 (en) 1993-07-22
FI943211A (fi) 1994-09-02
ES2164070T3 (es) 2002-02-16
DK0621898T3 (da) 2001-11-12
AU3340293A (en) 1993-08-03
PT621898E (pt) 2002-03-28
AU667502B2 (en) 1996-03-28
NO942530D0 (no) 1994-07-05
NO942530L (no) 1994-09-05
US20080015340A1 (en) 2008-01-17
FI117514B (fi) 2006-11-15
EP0621898B1 (de) 2001-09-12
RU2123047C1 (ru) 1998-12-10
DE69330745D1 (de) 2001-10-18
KR100208310B1 (ko) 1999-07-15
US5998169A (en) 1999-12-07
RU94042722A (ru) 1996-09-10
ATE205535T1 (de) 2001-09-15
WO1993014207A1 (en) 1993-07-22
US7405273B2 (en) 2008-07-29
JPH07501707A (ja) 1995-02-23
US6225091B1 (en) 2001-05-01
GB9200117D0 (en) 1992-02-26
NO316622B1 (no) 2004-03-15
US20080027213A1 (en) 2008-01-31
US5968776A (en) 1999-10-19
US7244589B2 (en) 2007-07-17
US6017539A (en) 2000-01-25
US6171783B1 (en) 2001-01-09
US20080311624A1 (en) 2008-12-18
US20050136067A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
DE69330745T2 (de) Chemerische immunogene
Weck et al. Antiviral activities of hybrids of two major human leukocyte interferons
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
DK0770679T3 (da) HCV-specifikke peptider, præparater indeholdende dem og anvendelse deraf
WO1992017493A3 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
DK251890A (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
ATE263243T1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
DE69515613D1 (de) Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
Dietzschold et al. Serological characterization of the three major proteins of vesicular stomatitis virus
EP0652287A3 (de) Poxvirusvektoren und deren Anwendung als Impstoff gegen Katzenansteckende Peritonitis-Viruskrankheit.
ATE342920T1 (de) Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
LU et al. Preparation and development of equine hyperimmune globulin F (ab′) 2 against severe acute respiratory syndrome coronavirus 1
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
EP1572721A4 (de) Prävention und behandlung von hcv-infektionen unter anwendung von gegen konformationelle und lineare epitope gerichteten antikörpern
ATE201693T1 (de) Hämoregulierende peptide
ATE133708T1 (de) Immunogenisches peptid von echinococcus granulosis, dafür kodierende dns sowie diagnostische und therapeutische verwendungen
MY101874A (en) Vaccine
WO1995005460A3 (en) Feline immunodeficiency virus isolate ncsu 1
DE69334276D1 (de) Immunreaktive peptide des epstein-barrvirus
HU9201590D0 (en) Recombinant vaccine against marek's illness
DK708488D0 (da) Faktor i praeparat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 621898

Country of ref document: EP